CN103694234A - 二氢嘧啶衍生物的晶型 - Google Patents

二氢嘧啶衍生物的晶型 Download PDF

Info

Publication number
CN103694234A
CN103694234A CN201310445326.0A CN201310445326A CN103694234A CN 103694234 A CN103694234 A CN 103694234A CN 201310445326 A CN201310445326 A CN 201310445326A CN 103694234 A CN103694234 A CN 103694234A
Authority
CN
China
Prior art keywords
crystal
powder diffraction
ray powder
crystal formation
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310445326.0A
Other languages
English (en)
Chinese (zh)
Inventor
张英俊
任青云
刘辛昌
王超磊
王天明
S·戈尔德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Priority to CN201310445326.0A priority Critical patent/CN103694234A/zh
Publication of CN103694234A publication Critical patent/CN103694234A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201310445326.0A 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型 Pending CN103694234A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310445326.0A CN103694234A (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210369019.4 2012-09-27
CN201210369019 2012-09-27
CN201310117076.8 2013-04-04
CN201310117076 2013-04-04
CN201310445326.0A CN103694234A (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Publications (1)

Publication Number Publication Date
CN103694234A true CN103694234A (zh) 2014-04-02

Family

ID=50355923

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201310445326.0A Pending CN103694234A (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201510364423.6A Active CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201310446506.0A Active CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510364423.6A Active CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201310446506.0A Active CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Country Status (20)

Country Link
US (1) US9403814B2 (enExample)
EP (1) EP2900664B1 (enExample)
JP (1) JP6310923B2 (enExample)
KR (1) KR20150060610A (enExample)
CN (3) CN103694234A (enExample)
AU (1) AU2013324779B2 (enExample)
BR (1) BR112015002979B8 (enExample)
CA (1) CA2881260C (enExample)
DK (1) DK2900664T3 (enExample)
ES (1) ES2660642T3 (enExample)
HU (1) HUE037285T2 (enExample)
MX (1) MX362829B (enExample)
MY (1) MY171497A (enExample)
PL (1) PL2900664T3 (enExample)
PT (1) PT2900664T (enExample)
RU (1) RU2646599C2 (enExample)
SG (1) SG11201500145TA (enExample)
TW (1) TWI561520B (enExample)
WO (1) WO2014048355A1 (enExample)
ZA (1) ZA201500290B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6113285B2 (ja) * 2012-09-10 2017-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン
WO2017076286A1 (zh) * 2015-11-04 2017-05-11 南京明德新药研发股份有限公司 二氢吡啶并环化合物的晶型、制备方法和中间体
CN107400125B (zh) * 2016-05-19 2020-02-11 广东东阳光药业有限公司 二氢嘧啶衍生物的晶型、盐和复合物及其在药物中的应用
CN107722109B (zh) * 2016-08-11 2020-12-18 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的晶型
US9856232B1 (en) * 2017-06-20 2018-01-02 King Saud University Dihydropyrimidinone derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154817A1 (en) * 2007-06-18 2008-12-24 Zhang, Zhongneng Bromo-phenyl substituted thiazolyl dihydropyrimidines
CN101744823A (zh) * 2008-12-17 2010-06-23 张中能 一种二氢嘧啶类化合物的固体分散体及其药用制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
CN101328170B (zh) 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
CN101328168B (zh) 2007-06-18 2011-09-07 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154817A1 (en) * 2007-06-18 2008-12-24 Zhang, Zhongneng Bromo-phenyl substituted thiazolyl dihydropyrimidines
CN101744823A (zh) * 2008-12-17 2010-06-23 张中能 一种二氢嘧啶类化合物的固体分散体及其药用制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
吕扬，等: "《晶型药物》", 31 October 2009 *
饶伟，等: "可激活并使HBV错配的杂环二氢嘧啶类药物", 《国外医学情报》 *

Also Published As

Publication number Publication date
ES2660642T3 (es) 2018-03-23
TW201412732A (zh) 2014-04-01
CA2881260A1 (en) 2014-04-03
EP2900664A1 (en) 2015-08-05
CN103724339A (zh) 2014-04-16
PT2900664T (pt) 2018-03-02
JP6310923B2 (ja) 2018-04-11
RU2015114085A (ru) 2016-11-20
CN104945394A (zh) 2015-09-30
RU2646599C2 (ru) 2018-03-06
US20150239877A1 (en) 2015-08-27
EP2900664A4 (en) 2016-03-09
ZA201500290B (en) 2016-10-26
CA2881260C (en) 2020-10-27
BR112015002979B1 (pt) 2020-12-22
DK2900664T3 (en) 2018-02-05
US9403814B2 (en) 2016-08-02
SG11201500145TA (en) 2015-02-27
AU2013324779B2 (en) 2015-10-08
JP2015531354A (ja) 2015-11-02
MY171497A (en) 2019-10-15
BR112015002979B8 (pt) 2022-03-03
KR20150060610A (ko) 2015-06-03
CN103724339B (zh) 2015-10-14
HUE037285T2 (hu) 2018-08-28
AU2013324779A1 (en) 2015-02-05
HK1207081A1 (en) 2016-01-22
EP2900664B1 (en) 2017-12-13
BR112015002979A2 (pt) 2017-07-04
WO2014048355A1 (en) 2014-04-03
MX362829B (es) 2019-02-14
TWI561520B (en) 2016-12-11
PL2900664T3 (pl) 2018-06-29
CN104945394B (zh) 2017-12-05
MX2015004115A (es) 2016-01-20

Similar Documents

Publication Publication Date Title
US10662198B2 (en) Polymorphic form of compound, preparation method and use thereof
KR101424013B1 (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법
US20040229777A1 (en) Crystalline phases of a potent HCV inhibitor
CN103724339B (zh) 二氢嘧啶衍生物的晶型
CN106810582B (zh) 吡喃葡萄糖基衍生物的复合物、制备方法和应用
CN105859708B (zh) 二氢嘧啶衍生物的盐及其在药物中的应用
CN120077045A (zh) 抗sars cov-2制剂的晶型
JP2014144916A (ja) ２−アシルアミノチアゾール化合物の結晶
JP2015508090A (ja) 固体形態のダビガトランエテキシレートメシレート及びその調製方法
TW202334143A (zh) 結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途
CN106674294A (zh) 吡喃葡萄糖基衍生物的结晶形式
CN107778336A (zh) 吡喃葡萄糖基衍生物的结晶形式
JP5959617B2 (ja) オタミキサバンの安息香酸塩
TW200526205A (en) Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient
CN105308043B (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN116162089B (zh) 嘧啶基抗病毒化合物的制备与使用方法
JP2020189888A (ja) キノロン類似体及びその塩の結晶形
HK1207081B (en) Crystalline forms of dihydropyrimidine derivatives
WO2015109925A1 (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2013103004A1 (ja) （２ｅ）－３－（１ｈ－インダゾール－３－イル）－ｎ－（３－メトキシフェニル）－ｎ－［３－（メチルスルホニル）プロピル］ブト－２－エンアミドの結晶形
TW201011015A (en) New compounds 500

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140402